Michael Mack was appointed Director of PROCEPT BioRobotics Corp. As of November 6, 2026, PROCEPT BioRobotics Corp has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on October 2, 2026, naming 1 appointment (Form 8-K, October 2, 2026).
PROCEPT BioRobotics Corp named a new Director on Oct 2. 30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like PROCEPT BioRobotics Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
PROCEPT BioRobotics Corp reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-10-02. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as PROCEPT BioRobotics Corp files it.
Also on the record for PROCEPT BioRobotics Corp
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 30, 2026 | Stake report, Schedule 13G/A, by Vanguard Capital Management | 4.96% of the class | 5%+ stakes | Source |
| July 29, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 8.2% of the class | 5%+ stakes | Source |
| May 18, 2026 | Stake report, Schedule 13G/A, by AllianceBernstein L.P. | 0.3% of the class | 5%+ stakes | Source |
| April 30, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| March 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 2.9% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by T. Rowe Price Investment Management, Inc. | 5.9% of the class | 5%+ stakes | Source |
| February 11, 2026 | Stake report, Schedule 13G, by BNP Paribas Asset Management Holding S.A. | 5.5% of the class | 5%+ stakes | Source |
| January 8, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 8.3% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G, by AllianceBernstein L.P. | 6.1% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs PROCEPT BioRobotics Corp now and the warning signs.
Free to see. No signup.
Keep reading
More on PROCEPT BioRobotics Corp and the records around it.
PROCEPT BioRobotics Corp elsewhere on the record
Companies that share a holder
- BNP Paribas Asset Management Holding S.A. also filed stake reports on 1 other company: Array Technologies, Inc. (Apr 2026)
- AllianceBernstein L.P. also filed stake reports on 82 other companies: New Fortress Energy Inc (Nov 2026), RIVERNORTH OPPORTUNITIES FUND, INC. (Oct 2026), Trex Co Inc (Sep 2026)
- T. Rowe Price Investment Management, Inc. also filed stake reports on 167 other companies: CABALETTA BIO INC (Nov 2026), MADISON SQUARE GARDEN SPORTS CORP (Nov 2026), MSG RANGERS CORP (Nov 2026)
Watch PROCEPT BioRobotics Corp
Get an email when PROCEPT BioRobotics Corp files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on PROCEPT BioRobotics Corp?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on PROCEPT BioRobotics Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on PROCEPT BioRobotics Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-02 | In | Director | 8-K, 2026-10-02 |
Who leads PROCEPT BioRobotics Corp, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Michael Mack, appointed (filed 2026-10-02).
New leaders reset buying decisions — get the Full Report on PROCEPT BioRobotics Corp: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at PROCEPT BioRobotics Corp, with the record behind each one.
Find candidates like Director at PROCEPT BioRobotics CorpEvery change, in the filing's words
Appointed: Michael Mack, Director
On October 2, 2026, the board of directors (the "Board") of PROCEPT BioRobotics Corporation (the "Company") approved (i) an increase in the size of the Board from nine members to ten members, (ii) appointed Dr. Michael Mack as a new member of the Board to fill the resulting vacancy, effective immediately.
- Dr. Mack was classified as a Class II director, and his initial term will expire at the Company's 2029 annual meeting of stockholders and until his successor has been elected and qualified, or until his earlier death, resignation or removal.
- The Board has determined that Dr. Mack is an "independent director" as defined under the applicable rules and regulations of the Securities and Exchange Commission ("SEC") and the listing requirements and rules of the Nasdaq stock market.
- Dr. Mack is a cardiac surgeon who has practiced in Dallas, Texas since 1982 and is board-certified in internal medicine, general surgery and thoracic surgery.
- He currently serves as Chairman of the Board of the Baylor Scott & White Research Institute and Associate Academic Officer of Baylor Scott & White Health.
- Dr. Mack also serves as Chair of the American Board of Thoracic Surgery, Co-Chair of the FDA Heart Valve Collaboratory, Senior Vice Chair of the National Institutes of Health's Cardiothoracic Surgical Trials Network, and a consultant to the Mussallem Congenital Heart Disease Alliance.
Tools for this story
Each opens in a new tab, filled in for PROCEPT BioRobotics Corp. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.